Abstract Background A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain. Methods Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8...
ABSTRACT: The study was conducted in order to evaluate the effect of a fipronil/(S)-methoprene formu...
AbstractFive controlled, blinded and randomized studies were conducted to examine the efficacy of a ...
Abstract Background The objective of these two GCP multicentre European clinical field studies was t...
Abstract Background A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/m...
Abstract Background Infestation of cats with the Australian paralysis tick, Ixodes holocyclus contin...
Abstract Background There is a continuing need for novel approaches to tick infestations treatment a...
Abstract Background Fluralaner (Bravecto®, Merck Animal Health, Madison, NJ, USA) is a novel isoxazo...
Abstract Background Lotilaner is a new isoxazoline developed as an oral ectoparasiticide for cats an...
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically appl...
Abstract Background Ticks are increasingly reported on cats worldwide, with Ixodes ricinus being a r...
Background: Fluralaner is a novel isoxazoline compound and the only systemically distributed ectopa...
Abstract Background The objectives of the studies listed here were to ascertain the therapeutic and ...
Abstract Background The efficacy of the fixed combination of fluralaner plus moxidectin for the trea...
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically appli...
Abstract Background Cats can be infested with several ectoparasite species, especially Ctenocephalid...
ABSTRACT: The study was conducted in order to evaluate the effect of a fipronil/(S)-methoprene formu...
AbstractFive controlled, blinded and randomized studies were conducted to examine the efficacy of a ...
Abstract Background The objective of these two GCP multicentre European clinical field studies was t...
Abstract Background A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/m...
Abstract Background Infestation of cats with the Australian paralysis tick, Ixodes holocyclus contin...
Abstract Background There is a continuing need for novel approaches to tick infestations treatment a...
Abstract Background Fluralaner (Bravecto®, Merck Animal Health, Madison, NJ, USA) is a novel isoxazo...
Abstract Background Lotilaner is a new isoxazoline developed as an oral ectoparasiticide for cats an...
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically appl...
Abstract Background Ticks are increasingly reported on cats worldwide, with Ixodes ricinus being a r...
Background: Fluralaner is a novel isoxazoline compound and the only systemically distributed ectopa...
Abstract Background The objectives of the studies listed here were to ascertain the therapeutic and ...
Abstract Background The efficacy of the fixed combination of fluralaner plus moxidectin for the trea...
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically appli...
Abstract Background Cats can be infested with several ectoparasite species, especially Ctenocephalid...
ABSTRACT: The study was conducted in order to evaluate the effect of a fipronil/(S)-methoprene formu...
AbstractFive controlled, blinded and randomized studies were conducted to examine the efficacy of a ...
Abstract Background The objective of these two GCP multicentre European clinical field studies was t...